Objective To evaluate the therapeutic effects and side-effects of rituximab combining with CHOP on B cell non-Hodgkin lymphoma.Methods A prospective study with concurrent control group was adopted.22 cases with B cell non-Hodgkin lymphoma were divided into 2 groups.The 11 cases in research group(rituximab group)were administered rituximab combining with CHOP(cyclophosphamide,doxorubicin,vincristine,and prednisone)regimen.The remaining 11 cases in the control group were treated with CHOP regimen only.All cases were received a course of 21 d and were evaluated after 6 coueses.The two groups were divided into high-risk and low-inter-mediate-risk subgroups according to the international prognosis index(IPI).Then we analyzed the relationship between the effects and IPI.Results The complete remission(CR)rate and total effective rate in rituximab group were 72.7% and 90.9% respectively,while those corresponding rates in control group were 36.4% and 54.5% respectively.The therapeutic differences between two groups showed statistical significance(P<0.001).Conclusion Comparing with CHOP regimen chemotherapy,rituximab combining CHOP regimen showes higher therapeutic effect.The side-effects were concordant in the two groups.Rituximab combining CHOP regimen should be the first choice in treating B cell non-Hodgkin lymphoma.